Toll Free: 1-888-928-9744

Oligodendroglioma - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Oligodendroglioma - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Oligodendroglioma - Pipeline Review, H2 2016', provides an overview of the Oligodendroglioma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma
- The report reviews pipeline therapeutics for Oligodendroglioma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Oligodendroglioma therapeutics and enlists all their major and minor projects
- The report assesses Oligodendroglioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Oligodendroglioma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Oligodendroglioma Overview 8 Therapeutics Development 9 Pipeline Products for Oligodendroglioma - Overview 9 Pipeline Products for Oligodendroglioma - Comparative Analysis 10 Oligodendroglioma - Therapeutics under Development by Companies 11 Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes 12 Oligodendroglioma - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Oligodendroglioma - Products under Development by Companies 15 Oligodendroglioma - Products under Investigation by Universities/Institutes 16 Oligodendroglioma - Companies Involved in Therapeutics Development 17 AngioChem Inc. 17 Axelar AB 18 Boehringer Ingelheim GmbH 19 Bristol-Myers Squibb Company 20 Cavion LLC 21 Celldex Therapeutics, Inc. 22 F. Hoffmann-La Roche Ltd. 23 Millennium Pharmaceuticals Inc 24 Novartis AG 25 Pfizer Inc. 26 Tocagen Inc. 27 Oligodendroglioma - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 afatinib dimaleate - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 alisertib - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 AXL-1717 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 bevacizumab - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 CDX-1401 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Cellular Immunotherapy for Gliomas - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Cellular Immunotherapy for Oncology - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 dasatinib - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 DNX-2401 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 flucytosine + TBio-01 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 irinotecan hydrochloride + TBio-02 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 mibefradil dihydrochloride - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 nilotinib - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 p28 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 paclitaxel trevatide - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 palbociclib - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Oligodendroglioma - Dormant Projects 113 Oligodendroglioma - Discontinued Products 114 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development for Oligodendroglioma, H2 2016 9 Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Oligodendroglioma - Pipeline by AngioChem Inc., H2 2016 17 Oligodendroglioma - Pipeline by Axelar AB, H2 2016 18 Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 19 Oligodendroglioma - Pipeline by Bristol-Myers Squibb Company, H2 2016 20 Oligodendroglioma - Pipeline by Cavion LLC, H2 2016 21 Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H2 2016 22 Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 23 Oligodendroglioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 24 Oligodendroglioma - Pipeline by Novartis AG, H2 2016 25 Oligodendroglioma - Pipeline by Pfizer Inc., H2 2016 26 Oligodendroglioma - Pipeline by Tocagen Inc., H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Assessment by Combination Products, H2 2016 29 Number of Products by Stage and Target, H2 2016 31 Number of Products by Stage and Mechanism of Action, H2 2016 33 Number of Products by Stage and Route of Administration, H2 2016 35 Number of Products by Stage and Molecule Type, H2 2016 37 Oligodendroglioma - Dormant Projects, H2 2016 113 Oligodendroglioma - Discontinued Products, H2 2016 114



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify